Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) issued its earnings results on Monday. The medical device company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. The firm had revenue of $24.29 million during the quarter, compared to analyst estimates of $25.48 million. Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.
Xtant Medical Stock Performance
Shares of XTNT opened at $0.27 on Monday. Xtant Medical has a 12-month low of $0.26 and a 12-month high of $0.84. The company has a quick ratio of 1.05, a current ratio of 2.16 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $38.12 million, a price-to-earnings ratio of -3.40 and a beta of -0.19. The stock’s 50-day moving average price is $0.32 and its 200 day moving average price is $0.44.
Wall Street Analyst Weigh In
Separately, Loop Capital set a $1.00 target price on shares of Xtant Medical in a research report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating. According to MarketBeat, Xtant Medical presently has an average rating of “Buy” and an average target price of $1.00.
View Our Latest Stock Report on Xtant Medical
About Xtant Medical
Xtant Medical Group, Inc. develops and markets medical products used in spine surgery. Its portfolio includes spinal implant systems and biologic products intended to support bone growth and spinal fusion. The company serves surgeons and healthcare providers, primarily in the United States, and also reaches select international markets through distribution relationships. Its products are used in procedures to treat spinal conditions and support stabilization or fusion. Xtant Medical’s business brings together spinal-device and biologics operations, including products developed through acquisitions.
Featured Stories
- Five stocks we like better than Xtant Medical
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
